Saturday, July 11, 2026

FDA · United States

diethylpropion hydrochloride — FDA regulatory status

diethylpropion hydrochloride (TENUATE) regulatory status in the United States is tracked from public FDA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: FDA approved.

Status snapshot

Status
FDA approved
Brand
TENUATE
Originator
Teva Pharma GmbH
Mechanism
Norepinephrine transporter inhibitor
Target
Sodium-dependent dopamine transporter
Structured fields
8

Sponsor / originator context: Teva Pharma GmbH. Pipeline programs and exclusivity signals below are joined from ClinicalTrials.gov-linked projects and USPTO/EPO patent rows associated with this INN.

Pharmacology context used for competitive intelligence: Norepinephrine transporter inhibitor. Target: Sodium-dependent dopamine transporter. This page is a status aggregation for professional reference — not prescribing advice.

Regional decision snapshot — FDA: approved.

Linked evidence on this spoke: 20 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.

Regulatory timeline

Regulator Region Status Date Source
FDA United States approved Evidence

Linked clinical programs

Related patents

Number Title Jurisdiction
12409213 Live attenuated oral vaccine against shigellosis and typhoid fever US
12383566 Inhibition of SLC transporter activity or expression to attenuate anthracycline-induced cardiotoxicity US
12102671 Method of vaccination with an attenuated RSV vaccine formulation US
12054519 Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes US
11813319 Development of a novel live attenuated African Swine Fever vaccine based in the deletion of gene I177L US
11801296 Development of a novel live attenuated African swine fever vaccine based in the deletion of gene A137R US
11793870 Live attenuated strains of foot and mouth disease modified by deoptimization and uses thereof US
11730801 Live attenuated Zika virus with 3'UTR deletion, vaccine containing and use thereof US
11478517 Live attenuated recombinant HMPV with mutations in PDZ motifs of M2-2 protein, vaccine containing and use thereof US
11331383 Attenuated african swine fever virus vaccine US
11318196 Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein US
11202825 Attenuated infectious bronchitis virus US

Related hubs

FAQ

What is the FDA approval status of diethylpropion hydrochloride?

diethylpropion hydrochloride currently shows FDA approved in our United States regulatory index. Confirm on the official FDA label or EPAR before clinical or commercial use.

Where does NovaPharmaNews get diethylpropion hydrochloride regulatory data?

Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.

How many clinical programs are linked to diethylpropion hydrochloride?

This spoke lists 20 published programs associated with diethylpropion hydrochloride in our pipeline index.